Welcome, Guest. Please login or register.
April 12, 2024, 05:13:24 pm

Login with username, password and session length

  • Total Members: 6307
  • Latest: golfer
  • Total Posts: 55125
  • Total Topics: 4851
  • Online Today: 61
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 37
Total: 37


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA Grants 'Priority Review' to Olysio & Sovaldi Hep C Combo  (Read 7079 times)

0 Members and 1 Guest are viewing this topic.

Offline iana5252

  • Administrator
  • Member
  • Posts: 187
The U.S. Food and Drug Administration (FDA) has granted priority review status to Medivir, in partnership with Janssen, for the supplemental New Drug Application (NDA) for Olysio (simeprevir) and Sovaldi (sofosbuvir) to treat genotype 1 of hepatitis C virus (HCV). On May 7, Medivir and Janssen filed the supplemental NDA for the 12-week, all-oral, interferon- and ribavirin-free regimen of the companies’ NS3/4A protease inhibitor Olysio and Gilead Sciences’ nucleotide analog polymerase inhibitor Sovaldi. The combination has already been widely prescribed off-label, but the FDA’s imprimatur would allow direct marketing of Olysio for this use.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.